IMDX · Insight Molecular Diagnostics Inc.
$4.32
+0.61 (+16.44%)
At close · Aug 14
Going-concern doubt
— cleared Aug 10, 2026
The latest filing states the doubt was alleviated.
“Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the consolidated financial statements are issued. ... Management has concluded that it is probable that our plans will be effectively implemented and that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date of issuance of these consolidated financial statements. ... Accordingly, management has concluded that substantial doubt does not exist about the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 10, 2026
Market Cap
$141.37M
Shares
32.72M
Insight Molecular Diagnostics Inc. Earnings Call Transcripts
Every quarterly earnings call for Insight Molecular Diagnostics Inc. (IMDX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼88.3%
$237,000
−$8.30M
'22 Q2
22-08-10
▼93.2%
$67,000
−$9.33M
'22 Q3
22-11-10
▼92.4%
$274,000
−$44.98M
'22 Q4
23-04-03
▼21.8%
$297,000
$3.03M
'23 Q1
23-04-05
▲95.4%
$463,000
−$8.33M
'23 Q2
23-08-10
▲540.3%
$429,000
−$6.49M
'23 Q3
23-11-09
▼40.7%
$176,000
−$9.13M
'24 Q1
24-04-12
▼77.5%
$104,000
−$4.53M
'24 Q2
24-08-08
▼73.2%
$115,000
−$13.49M
'24 Q3
24-11-12
▲373.2%
$1.49M
−$33.51M
'24 Q4
25-03-24
▲1114.8%
$2.14M
−$6.67M
'25 Q1
25-05-12
▲398.1%
$518,000
−$9.74M
'25 Q2
25-08-11
▲126.1%
$260,000
−$10.85M
'25 Q3
25-11-10
▼23.4%
$1.14M
−$22.95M
'25 Q4
26-03-26
▼98.5%
$32,000
−$4.29M
'26 Q1
26-05-13
LATEST
▼53.9%
$239,000
−$11.26M
'26 Q2
26-08-10
Earnings call
FY26 · Q2
2026-08-10
Insight Molecular Diagnostics - Second Quarter 2026 Earnings Conference Call
Revenue
$239,000
▼ 53.9% YoY Diluted EPS
$-0.31
Gross margin
65.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Insight Molecular Diagnostics Inc. Q1 FY2026 Earnings Call
Confident tone
GraftAssure DX FDA Review and Launch
International Market Access and Reimbursement
Financial Outlook and Cash Burn
Revenue
$32,000
▼ 98.5% YoY Diluted EPS
$-0.12
Gross margin
46.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-26
Insight Molecular Diagnostics Inc. Q4 FY2025 Earnings Call
Confident tone
FDA submission of GraftAssure DX
Galactic registry and center engagement
Reimbursement and billing pathway
Revenue
$1.14M*
▼ 23.4% YoY Gross margin
43.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Insight Molecular Diagnostics Inc. Q3 FY2025 Earnings Call
Confident tone
FDA Submission and Government Shutdown Risk
Expenses, Cash Burn, and 2026 Planning
Head-to-Head Comparison Data
Revenue
$260,000
▲ 126.1% YoY Diluted EPS
$-0.34
Gross margin
53.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Insight Molecular Diagnostics Inc. Q2 FY2025 Earnings Call
Confident tone
FDA submission and ReftAssure DX clinical trial
Multi-organ indication expansion (kidney, heart, lung)
World Transplant Congress and Charite research partnership
Revenue
$518,000
▲ 398.1% YoY Diluted EPS
$-0.30
Gross margin
65.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Insight Molecular Diagnostics Inc. Q1 FY2025 Earnings Call
Confident tone
FDA submission and clinical trial progress
Antibody-mediated rejection and CD38 drug opportunity
GraftAssure RUO land-and-expand strategy
Revenue
$2.14M
▲ 1114.8% YoY Diluted EPS
$-0.26
Gross margin
62.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-24
Insight Molecular Diagnostics Inc. Q4 FY2024 Earnings Call
Confident tone
FDA regulatory pathway and timeline
Graft Assure RUO kit and product development
Transplant center sign-ups and commercial pipeline
Revenue
$1.49M*
▲ 373.2% YoY Gross margin
40.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Insight Molecular Diagnostics Inc. Q3 FY2024 Earnings Call
Revenue
$115,000
▼ 73.2% YoY Diluted EPS
$-0.98
Gross margin
43.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Insight Molecular Diagnostics Inc. Q2 FY2024 Earnings Call
Revenue
$104,000
▼ 77.5% YoY Diluted EPS
$-0.36
Gross margin
48.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-12
Insight Molecular Diagnostics Inc. Q1 FY2024 Earnings Call
Revenue
$176,000
▼ 40.7% YoY Diluted EPS
$-1.13
▼ 382.5% YoY Gross margin
25.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q3
2023-11-09
Insight Molecular Diagnostics Inc. Q3 FY2023 Earnings Call
Revenue
$429,000
▲ 540.3% YoY Diluted EPS
$-0.81
Gross margin
57.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Insight Molecular Diagnostics Inc. Q2 FY2023 Earnings Call
Revenue
$463,000
▲ 95.4% YoY Diluted EPS
$-1.07
Gross margin
58.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-05
Insight Molecular Diagnostics Inc. Q1 FY2023 Earnings Call
Revenue
$297,000
▼ 21.8% YoY Diluted EPS
$0.40
Gross margin
3.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-04-03
Insight Molecular Diagnostics Inc. Q4 FY2022 Earnings Call
Revenue
$274,000*
▼ 92.4% YoY Gross margin
-9.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Insight Molecular Diagnostics Inc. Q3 FY2022 Earnings Call
Revenue
$67,000
▼ 93.2% YoY Diluted EPS
$-1.62
Gross margin
-401.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Insight Molecular Diagnostics Inc. Q2 FY2022 Earnings Call
Revenue
$237,000
▼ 88.3% YoY Diluted EPS
$-1.48
Gross margin
13.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Insight Molecular Diagnostics Inc. Q1 FY2022 Earnings Call
Revenue
$380,000
▼ 66.2% YoY Diluted EPS
$-2.20
Gross margin
65.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Insight Molecular Diagnostics Inc. Q4 FY2021 Earnings Call
Revenue
$3.59M
▲ 613.5% YoY Gross margin
72.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Insight Molecular Diagnostics Inc. Q3 FY2021 Earnings Call
Revenue
$984,000
▲ 77.3% YoY Gross margin
-88.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Insight Molecular Diagnostics Inc. Q2 FY2021 Earnings Call
Revenue
$2.03M
▲ 1319.6% YoY Gross margin
-19.4%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-17
Insight Molecular Diagnostics Inc. Q1 FY2021 Earnings Call
Revenue
$1.12M
▲ 6925% YoY Gross margin
7.0%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-16
Insight Molecular Diagnostics Inc. Q4 FY2020 Earnings Call
Revenue
$503,000
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Insight Molecular Diagnostics Inc. Q3 FY2020 Earnings Call
Revenue
$555,000
Gross margin
-8.3%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Insight Molecular Diagnostics Inc. Q2 FY2020 Earnings Call
Revenue
$143,000
Gross margin
-155.2%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Insight Molecular Diagnostics Inc. Q1 FY2020 Earnings Call
Revenue
$16,000
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-25
Insight Molecular Diagnostics Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–26 of 26 earnings calls
Key facts
CIK
1642380
CUSIP
68235C206
13F (30d)
37 filings
37 filers
Visit website
Investor relations